(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.32%) $79.20
(-1.03%) $2.01
(0.09%) $2 311.60
(0.23%) $26.89
(0.52%) $967.60
(-0.10%) $0.931
(-0.14%) $10.98
(-0.14%) $0.797
(1.51%) $92.51
Live Chart Being Loaded With Signals
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N...
Stats | |
---|---|
आज की मात्रा | 509 800 |
औसत मात्रा | 1.11M |
बाजार मूल्य | 7.01B |
EPS | HKD-0.580 ( 2023-10-30 ) |
Last Dividend | HKD0.937 ( 2022-07-13 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -3.29 |
ATR14 | HKD0.0540 (0.25%) |
मात्रा सहसंबंध
Cansino Biologics Inc सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध |
---|
10 सबसे अधिक नकारात्मक सहसंबंध |
---|
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Cansino Biologics Inc सहसंबंध - मुद्रा/वस्त्र
Cansino Biologics Inc वित्तीय
Annual | 2023 |
राजस्व: | HKD345.18M |
सकल लाभ: | HKD-876.02M (-253.78 %) |
EPS: | HKD-6.01 |
FY | 2023 |
राजस्व: | HKD345.18M |
सकल लाभ: | HKD-876.02M (-253.78 %) |
EPS: | HKD-6.01 |
FY | 2022 |
राजस्व: | HKD1.03B |
सकल लाभ: | HKD-186.61M (-18.10 %) |
EPS: | HKD-3.91 |
FY | 2021 |
राजस्व: | HKD4.30B |
सकल लाभ: | HKD3.00B (69.85 %) |
EPS: | HKD7.74 |
Financial Reports:
No articles found.
Cansino Biologics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.937 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.937 | 2022-07-13 |
Last Dividend | HKD0.937 | 2022-07-13 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | HKD0.937 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2888.HK | Ex Dividend Junior | 2023-08-10 | Annually | 0 | 0.00% | |
1503.HK | Ex Dividend Junior | 2023-09-13 | Semi-Annually | 0 | 0.00% | |
0552.HK | Ex Dividend Junior | 2023-07-03 | Annually | 0 | 0.00% | |
8223.HK | Ex Dividend Junior | 2023-06-08 | Annually | 0 | 0.00% | |
2009.HK | No Dividend Player | 2023-05-18 | Annually | 0 | 0.00% | |
1083.HK | Ex Dividend Junior | 2023-05-30 | Annually | 0 | 0.00% | |
0151.HK | Ex Dividend Knight | 2023-08-24 | Semi-Annually | 0 | 0.00% | |
3709.HK | Ex Dividend Knight | 2023-06-14 | Annually | 0 | 0.00% | |
1651.HK | Ex Dividend Knight | 2023-08-22 | Semi-Annually | 0 | 0.00% | |
0688.HK | Ex Dividend Knight | 2023-09-18 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -4.24 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.159 | 1.200 | -5.30 | -6.36 | [0 - 0.3] |
returnOnEquityTTM | -0.252 | 1.500 | -3.91 | -5.86 | [0.1 - 1] |
payoutRatioTTM | -0.0725 | -1.000 | -0.725 | 0.725 | [0 - 1] |
currentRatioTTM | 1.999 | 0.800 | 5.01 | 4.00 | [1 - 3] |
quickRatioTTM | 1.835 | 0.800 | 3.91 | 3.13 | [0.8 - 2.5] |
cashRatioTTM | 0.790 | 1.500 | 6.72 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.290 | -1.500 | 5.17 | -7.76 | [0 - 0.6] |
interestCoverageTTM | -37.09 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -3.62 | 2.00 | -1.207 | -2.41 | [0 - 30] |
freeCashFlowPerShareTTM | -6.10 | 2.00 | -3.05 | -6.10 | [0 - 20] |
debtEquityRatioTTM | 0.512 | -1.500 | 7.95 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | -1.411 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -3.70 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.330 | 1.000 | -2.95 | -2.95 | [0.2 - 2] |
assetTurnoverTTM | 0.0376 | 0.800 | -3.08 | -2.47 | [0.5 - 2] |
Total Score | -3.45 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -2.98 | 1.000 | -0.402 | 0 | [1 - 100] |
returnOnEquityTTM | -0.252 | 2.50 | -2.51 | -5.86 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -6.10 | 2.00 | -2.03 | -6.10 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -3.62 | 2.00 | -1.207 | -2.41 | [0 - 30] |
payoutRatioTTM | -0.0725 | 1.500 | -0.725 | 0.725 | [0 - 1] |
pegRatioTTM | 0.173 | 1.500 | -2.18 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -2.55 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.75 |
Cansino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं